Citigroup
RLMD icon

Citigroup’s Relmada Therapeutics RLMD Stock Holding History

Citigroup’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497K Buy
71,753
+56,339
+366% +$394K ﹤0.01% 3904
2026
Q1 		$107K Sell
15,414
-7,120
-32% -$33.7K ﹤0.01% 4255
2025
Q4 		$109K Buy
22,534
+22,532
+1,126,600% +$75.5K ﹤0.01% 4284
2025
Q3 		$4 Hold
2
– – ﹤0.01% 5994
2025
Q2 		$1 Hold
2
– – ﹤0.01% 5616
2025
Q1 		$1 Sell
2
-62,947
-100% -$20.9K ﹤0.01% 5528
2024
Q4 		$32.7K Sell
62,949
-2
-0% -$5 ﹤0.01% 5189
2024
Q3 		$204K Hold
62,951
– – ﹤0.01% 4332
2024
Q2 		$189K Sell
62,951
-60,862
-49% -$220K ﹤0.01% 3903
2024
Q1 		$576K Buy
123,813
+50,690
+69% +$244K ﹤0.01% 3467
2023
Q4 		$303K Sell
73,123
-26,400
-27% -$78.2K ﹤0.01% 3721
2023
Q3 		$299K Sell
99,523
-19,795
-17% -$58.8K ﹤0.01% 3417
2023
Q2 		$294K Buy
+119,318
New +$330K ﹤0.01% 3690
2023
Q1 		– Sell
-185
Closed -$646 – 5805
2022
Q4 		$646 Sell
185
-3,997
-96% -$35.1K ﹤0.01% 5469
2022
Q3 		$155K Sell
4,182
-58,519
-93% -$1.62M ﹤0.01% 3883
2022
Q2 		$1.19M Buy
62,701
+27,796
+80% +$606K ﹤0.01% 2515
2022
Q1 		$942K Buy
34,905
+29,891
+596% +$618K ﹤0.01% 3029
2021
Q4 		$113K Sell
5,014
-2,887
-37% -$64.2K ﹤0.01% 4669
2021
Q3 		$207K Buy
7,901
+4,166
+112% +$112K ﹤0.01% 4098
2021
Q2 		$120K Buy
3,735
+1,975
+112% +$68.6K ﹤0.01% 4449
2021
Q1 		$62K Sell
1,760
-2,748
-61% -$96.1K ﹤0.01% 4599
2020
Q4 		$144K Buy
4,508
+1,909
+73% +$65.6K ﹤0.01% 5243
2020
Q3 		$98K Sell
2,599
-2,423
-48% -$93.6K ﹤0.01% 5134
2020
Q2 		$224K Buy
5,022
+3,322
+195% +$140K ﹤0.01% 4929
2020
Q1 		$58K Buy
1,700
+764
+82% +$30.8K ﹤0.01% 5849
2019
Q4 		$37K Buy
+936
New +$28.4K ﹤0.01% 6562

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's RLMD Position: Q2 2026 in Review

Citigroup increased its Relmada Therapeutics (RLMD) stake by 366% in Q2 2026, buying an estimated $394K and bringing the position to 71,753 shares worth $497K. The position accounts for ﹤0.01% of the portfolio, ranked #3904.

Citigroup first reported a position in RLMD in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.19M in Q2 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Citigroup held 71,753 shares of Relmada Therapeutics worth $497K as of Q2 2026.
  • Citigroup bought 56,339 Relmada Therapeutics shares in Q2 2026, an estimated $394K.
  • Relmada Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3904 holding.
  • Citigroup first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Citigroup's Relmada Therapeutics position peaked at $1.19M in Q2 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.